In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 141-30-0, name is 3,6-Dichloropyridazine, introducing its new discovery. Recommanded Product: 3,6-Dichloropyridazine
The invention relates to novel 3(2H)-pyridazinone-derivatives of the general formula (I), pharmaceutical compositions containing them and process for their preparation. In the general formula (I) STR1 stands for an ethyl or propyl group substituted by a terminal halogen atom or a hydroxyl or NR1 R2 group, wherein R1 represents hydrogen atom or an unsubstituted or optionally substituted benzyl group; R2 represents hydrogen atom or an unsubstituted or optionally substituted benzo[1,4]dioxan-2-yl-methyl or -ethyl group or a (CH2)n –R3 group, wherein n is 2 or 3; and R3 stands for an unsubstituted or optionally substituted phenoxy or phenylthio group; and X stands for a hydrogen or halogen atom or an unsubstituted or optionally substituted, saturated or unsaturated 5- or 6-membered heterocyclic group containing a nitrogen atom and optionally an additional heteroatom, e.g. an oxygen, sulfur or nitrogen atom, with the proviso that R is different from an ethyl or propyl group substituted terminally by a hydroxyl group or halogen atom when X represents a hydrogen or chlorine atom. The compounds of general formula (I) selectively inhibit the adrenergic alpha1 receptors, have a calcium-antagonistic effect and exert blood pressure lowering action.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 141-30-0, and how the biochemistry of the body works.Recommanded Product: 3,6-Dichloropyridazine
Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N1387 – PubChem